Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL610140

CCCC[N+](CCCC)(CCCC)CCCC.O=P([O-])(O)O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 3/20 0.60
SLC22A2 O15244 1/20 0.52
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
CYP3A4 P08684 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HIF1A Q16665 1/20 0.48
HSD17B10 Q99714 1/20 0.48
LPAR3 Q9UBY5 4/20 0.46
LPAR2 Q9HBW0 1/20 0.46
DNM1 Q05193 4/20 0.44
FDPS P14324 1/20 0.43
LPAR1 Q92633 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL3795558 0.98 SLC22A1 (0.57) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL8055058 0.98 SLC22A1 (0.57) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL29278257 0.98 SLC22A1 (0.57) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL29018271 0.95 SLC22A1 (0.55) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL28465671 0.95 SLC22A1 (0.55) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL29164942 0.95 SLC22A1 (0.55) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL28110683 0.95 SLC22A1 (0.55) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL29164919 0.95 SLC22A1 (0.55) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL29036254 0.95 SLC22A1 (0.55) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL28738440 0.95 SLC22A1 (0.55) SLC22A1SLC22A2ALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1898 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079810-A Aromatic diamine and polyimide containing amido, preparation method and application thereof 2026-05-26 CN claimed
EP-4690281-A1 COMPOSITION FOR TIN HARD MASK REMOVAL WHILE COMPATIBLE WITH TUNGSTEN Versum Materials US, LLC (US) 2026-02-11 EP claimed
US-12546746-B2 Systems and devices for estimating substance concentration EKIDNA SENSING INC. (CA) 2026-02-10 US claimed
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES ENTEGRIS INC (US) 2026-01-15 US claimed
US-20250388596-A1 PROCESS FOR THE EXTRACTION AND PURIFICATION OF TETRODOTOXIN WEX PHARMACEUTICALS INC (CA) 2025-12-25 US claimed
US-20250382711-A1 METHOD OF PREPARING 2-HYDROXYADPIC ACID AND ADIPIC ACID NATIONAL CHENG KUNG UNIVERSITY (TW) 2025-12-18 US claimed
US-20250362278-A1 MASS SPECTROMETRY OF MRNA MODERNATX, INC. (US) 2025-11-27 US claimed
EP-4605578-A2 ELECTROCATALYTIC GENERATION OF IMINES FROM ALCOHOLS AND AMINES Université Paris Cité (FR) 2025-08-27 EP claimed
EP-4565694-A1 EXTRACTION-LESS REVERSE PHASE (RP) CHROMATOGRAPHY FOR MRNA PURITY ASSESSMENT ModernaTX, Inc. (US) 2025-06-11 EP claimed
CN-118773626-B Method for preparing adiponitrile by electrolyzing acrylonitrile based on anode sacrificial agent 重庆大学 2025-06-03 CN claimed
EP-1425310-A2 WATER SOLUBLE, RANDOMLY SUBSTITUTED PARTIAL N-, PARTIAL O-ACETYLATED CHITOSAN, PRESERVING COMPOSITIONS CONTAINING CHITOSAN, AND PROCESSES FOR MAKING THEREOF Technology Resource International Corporation (US) 2004-06-09 EP claimed
US-6716970-B2 CONTACT LENS PRESERVATIVE SOLUTION ADJUVANT PHARMACEUTICALS, LLC 2004-04-06 US claimed
US-20020177577-A1 Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof ADJUVANT PHARMACEUTICALS, LLC 2002-11-28 US claimed
WO-2002085951-A2 WATER SOLUBLE, RANDOMLY SUBSTITUTED PARTIAL N-, PARTIAL O-ACETYLATED CHITOSAN, PRESERVING COMPOSITIONS CONTAINING CHITOSAN, AND PROCESSES FOR MAKING THEREOF TECHNOLOGY RESOURCE INTERNATIONAL CORPORATION (US) 2002-10-31 WO claimed
US-20020018732-A1 Preserving compositions containing chitosan and processes for making water soluble O-acetylated chitosan and chitosan TECHNOLOGY RESOURCE INTERNATIONAL CORPORATION 2002-02-14 US claimed
EP-0877298-B1 Coated xerographic photographic paper XEROX CORP (US) 2001-08-29 EP claimed
US-5908723-A Recording sheets XEROX CORPORATION (US) 1999-06-01 US claimed
US-5846637-A Coated xerographic photographic paper XEROX CORPORATION (US) 1998-12-08 US claimed
EP-0877298-A2 Coated xerographic photographic paper Xerox Corporation (US) 1998-11-11 EP claimed
EP-0367447-A1 Human epithelial transforming growth factor SMITHKLINE BEECHAM CORPORATION (US) 1990-05-09 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177577-A1 Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof PIGS, CSGALNACT1, OGA SLC22A1 3151/4885SLC22A2 3349/4885ALDH1A1 2810/4885
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES TET2, ASIC1, PIEZO1 SLC22A1 2747/4885SLC22A2 2992/4885ALDH1A1 789/4885
US-12546746-B2 Systems and devices for estimating substance concentration CNR2, CNR1, NCS1 SLC22A1 3444/4885SLC22A2 3375/4885ALDH1A1 1563/4885
US-20250388596-A1 PROCESS FOR THE EXTRACTION AND PURIFICATION OF TETRODOTOXIN TRPA1, CACNA1D, SCN2A SLC22A1 3782/4885SLC22A2 3591/4885ALDH1A1 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.